Pharmacological treatment of Parkinson disease: a review.

  title={Pharmacological treatment of Parkinson disease: a review.},
  author={Barbara S. Connolly and Anthony E. Lang},
  volume={311 16},
IMPORTANCE Parkinson disease is the second most common neurodegenerative disease worldwide. [] Key MethodEVIDENCE REVIEW References were identified using searches of PubMed between January 1985 and February 2014 for English-language human studies and the full database of the Cochrane Library. The classification of studies by quality (classes I-IV) was assessed using the levels of evidence guidelines from the American Academy of Neurology and the highest-quality data for each topic.

Figures and Tables from this paper

Pharmacological Treatment in Parkinson’s Disease
  • J. J. Lee
  • Biology, Psychology
    Journal of the Korean Neurological Association
  • 2019
Evidence-based review of pharmacological treatment of Parkinson’s disease from early to advanced stages as well as management its unavoidable adverse reactions are provided.
Treating the Motor Symptoms of Parkinson Disease
Treatment of PD is multifaceted and requires a tailored pharmacotherapeutic and nonpharmacologic approach for a given patient, and clinicians should try to provide optimum benefit through the many treatment options available.
Initial management of Parkinson’s disease
Research is under way to deliver dopaminergic therapy more effectively, but studies aimed at slowing or stopping disease progression have not shown promise.
Pharmacological management of Parkinson’s disease in older people
An evidence‐based review of Parkinson’s disease treatments and guidance to improve clinical management and outcomes in older people is presented.
Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis
A systematic review of prospective, randomised controlled trials found that ChIs are effective in the treatment of cognitive impairment in patients with PD, but do not affect risk of falls.
Treatment of Older Parkinson's Disease.
Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease
Existing and emerging pharmacotherapies for motor symptoms in PD are outlined and newer medications and modes of delivery continue to be researched and added to the therapeutic armamentarium.
Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition
A literature review on the most recent knowledge with special focus on specific clinical subtypes and pathophysiological mechanisms of PD psychosis will not only contribute to an up to date practical approach of this condition for the health care providers, but furthermore open up new ideas for research in the near future.
Effects of Genetic Variability in Dopaminergic Pathway on Treatment Response in Parkinson’s Disease
Several polymorphic genes have already been associated with treatment outcome in PD, such as metabolic enzymes, transport and receptor genes, and might serve as treatment outcome prediction factors and help in personalized care of PD patients to prevent adverse events and inefficacy of a certain drug.


An update expert opinion on management and research strategies in Parkinson's disease psychosis
Novel research strategies focus on nondopaminergic systems and incorporate neuroimaging, genetic associations and animal models and have the potential to enhance understanding of PD psychosis and advance the development of agents that can ultimately be tested in well-designed, randomized, controlled trials.
Impact of standard of care for psychosis in Parkinson disease
A group of 26 patients with idiopathic PD, initially referred for participation in a study of quetiapine as a treatment for psychotic symptoms in PD patients, were evaluated using a separate investigator-initiated protocol, finding no previous studies have formally evaluated the validity of this approach.
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
The case of Mr L, a man with an 11-year history of Parkinson disease, illustrates these emerging motor complications and the manner in which they may be managed both medically and surgically.
Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
There is insufficient evidence to support or refute the efficacy of DBS of the GPi or VIM nucleus of the thalamus in reducing off time, dyskinesia, or medication usage, or to improve motor function.
Management of hallucinations and psychosis in Parkinson's disease.
  • M. Eng, T. Welty
  • Psychology, Medicine
    The American journal of geriatric pharmacotherapy
  • 2010
Zonisamide in managing impulse control disorders in Parkinson’s disease
It is suggested that ZNS may be effective for ICDs in PD, and the lack of studies with other medications to treat these behaviours in PD and the potential beneficial effects of ZNS for motor complications make this drug important in the treatment of the disease.
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
This interventional study provides Class II evidence that atomoxetine (target dosage = 80 mg/day) is not efficacious in improving clinically significant depression in PD, but was associated with improvement in global cognitive performance and daytime sleepiness.
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005 and highlights gaps for research.
A controlled trial of antidepressants in patients with Parkinson disease and depression
The trial suggests that depression in patients with PD is responsive to treatment and raises questions about the relative efficacy of dual reuptake inhibitors and selective serotonin reuptakes inhibitors.